ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than av

Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun conc

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

ImmunityBio, Inc. ((

ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary res

The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data sho

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC w

ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key blad

NAI+BCG versus Nadofaragene Results:NAI+BCG treated patients were twice as likely to achieve a compl

ImmunityBio secures exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG, aiming to end

Five issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) wit

Positive Phase III readout of National Cancer Institute-sponsored SWOG S1602 randomized clinical tri

ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and upd

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst co

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst co

ImmunityBio (IBRX) stock is surging. Read why Patrick Soon-Shiong's manufacturing updates and ne

Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide

The Avis Budget short squeeze appears to be spreading to other stocks like Beyond Meat, Opendoor and

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after it launched ANKTIVA in Saudi

ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning pro

ImmunityBio responds to FDA warning on Anktiva promotions, while NCCN update and rising sales suppor

Company initiated a comprehensive review of promotional materials and is implementing enhanced adver

Shares of ImmunityBio, Inc. (NASDAQ: IBRX) are lifting after the company announced it secured $75 mi

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, t

ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, t

ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the comp

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/i

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patie

The NCCN adds ImmunityBio Anktiva plus BCG to bladder cancer guidelines, expanding treatment use and

ImmunityBio stock rises in premarket after NK cell therapy trials show safety and scalable productio

U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-

BTIG analyst Jeet Mukherjee assumes ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Pr

ImmunityBio resubmits the ANKTIVA application to the FDA after a prior setback.

Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by

Piper Sandler analyst Edward Tenthoff reiterates ImmunityBio (NASDAQ:IBRX) with a Overweight and

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3

ImmunityBio stock rises after 85% response rate in bladder cancer study, topping BCG alone; FDA fili

ImmunityBio ((

ImmunityBio stock climbs after Anktiva sales surge 750%, revenue beats estimates, and new Saudi part

With 40% short interest and rising hedge fund buying, ImmunityBio's explosive rally may be enter

ImmunityBio shares surge on 700% revenue growth driven by sales of Anktiva, the company's approv